Kymera Therapeutics Inc (KYMR)vsRegeneron Pharmaceuticals Inc (REGN)
KYMR
Kymera Therapeutics Inc
$114.96
-1.74%
HEALTHCARE · Cap: $9.58B
REGN
Regeneron Pharmaceuticals Inc
$781.49
-1.48%
HEALTHCARE · Cap: $80.46B
Smart Verdict
WallStSmart Research — data-driven comparison
Regeneron Pharmaceuticals Inc generates 14695% more annual revenue ($15.53B vs $105.00M). REGN leads profitability with a 27.9% profit margin vs -285.3%. REGN earns a higher WallStSmart Score of 66/100 (B-).
KYMR
Avoid30
out of 100
Grade: F
REGN
Strong Buy66
out of 100
Grade: B-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+24.1%
Fair Value
$108.47
Current Price
$114.96
$6.49 discount
Margin of Safety
+44.4%
Fair Value
$1404.34
Current Price
$781.49
$622.85 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 466.4% year-over-year
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Strong operational efficiency at 33.1%
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Large-cap with strong market position
Keeps 28 of every $100 in revenue as profit
Reasonable price relative to book value
Areas to Watch
0.0% earnings growth
Weak financial health signals
ROE of -20.5% — below average capital efficiency
Negative free cash flow — burning cash
Weak financial health signals
Earnings declined 4.5%
Comparative Analysis Report
WallStSmart ResearchBull Case : KYMR
The strongest argument for KYMR centers on Revenue Growth, Debt/Equity, Altman Z-Score. Revenue growth of 466.4% demonstrates continued momentum.
Bull Case : REGN
The strongest argument for REGN centers on Operating Margin, Debt/Equity, Altman Z-Score. Profitability is solid with margins at 27.9% and operating margin at 33.1%. Revenue growth of 16.7% demonstrates continued momentum.
Bear Case : KYMR
The primary concerns for KYMR are EPS Growth, Piotroski F-Score, Return on Equity.
Bear Case : REGN
The primary concerns for REGN are Piotroski F-Score, EPS Growth.
Key Dynamics to Monitor
KYMR profiles as a hypergrowth stock while REGN is a growth play — different risk/reward profiles.
KYMR carries more volatility with a beta of 1.97 — expect wider price swings.
KYMR is growing revenue faster at 466.4% — sustainability is the question.
REGN generates stronger free cash flow (334M), providing more financial flexibility.
Bottom Line
REGN scores higher overall (66/100 vs 30/100), backed by strong 27.9% margins and 16.7% revenue growth. KYMR offers better value entry with a 24.1% margin of safety. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Kymera Therapeutics Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Kymera Therapeutics, Inc., a biopharmaceutical company, is focused on discovering and developing new small molecule treatments that selectively break down disease-causing proteins by harnessing the body's own natural protein breakdown system. The company is headquartered in Watertown, Massachusetts.
Visit Website →Regeneron Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester County, New York. Originally focused on neurotrophic factors and their regenerative capabilities, giving rise to its name, the company then branched out into the study of both cytokine and tyrosine kinase receptors.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?